Your browser doesn't support javascript.
loading
Tocilizumab Exerts Anti-Tumor Effects on Colorectal Carcinoma Cell Xenografts Corresponding to Expression Levels of Interleukin-6 Receptor.
Chung, Yuan-Chiang; Chen, Szu-Jung; Huang, Chiu-Chen; Liu, Wei-Chun; Lai, Ming-Tsung; Kao, Ting-Yu; Yang, Wei-Shun; Yang, Chien-Hui; Hsu, Chih-Ping; Chang, Jia-Feng.
Afiliação
  • Chung YC; Department of Surgery, Kuang Tien General Hospital, Taichung 433, Taiwan.
  • Chen SJ; Department of Surgery, Chung-Kang Branch, Cheng-Ching General Hospital, Taichung 407, Taiwan.
  • Huang CC; Department of Radiation Oncology, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan 330, Taiwan.
  • Liu WC; Department of Post-Baccalaureate Veterinary Medicine, Asia University, Taichung 413, Taiwan.
  • Lai MT; Department of Pathology, Hsin-Chu Branch, National Taiwan University Hospital, Hsinchu 300, Taiwan.
  • Kao TY; Department of Pathology, Taichung Hospital, Ministry of Health and Welfare, Taichung 403, Taiwan.
  • Yang WS; Department of Medical Laboratory Science and Biotechnology, Yuanpei University of Medical Technology, Hsinchu 300, Taiwan.
  • Yang CH; Department of Internal Medicine, Hsin-Chu Branch, National Taiwan University Hospital, Hsinchu 300, Taiwan.
  • Hsu CP; Department of Business Administration, Yuanpei University of Medical Technology, Hsinchu 300, Taiwan.
  • Chang JF; Department of Medical Laboratory Science and Biotechnology, Yuanpei University of Medical Technology, Hsinchu 300, Taiwan.
Pharmaceuticals (Basel) ; 17(1)2024 Jan 18.
Article em En | MEDLINE | ID: mdl-38256960
ABSTRACT
The use of tocilizumab against the interleukin-6 receptor (IL-6R) has been demonstrated as inhibiting the progression of diverse cancers in vitro and in vivo. Nonetheless, evidence regarding the anti-tumor effects of tocilizumab on human colorectal carcinoma (CRC) corresponding to IL-6R expression levels remains scarce. To investigate the influence of IL-6R expression, SW480 and HT-29 cells inoculated subcutaneously into NU/NU mice were used as human CRC xenograft models with anti-IL-6R antibody (tocilizumab) therapy. The IL-6R expression levels, histology of CRC growth/invasiveness, and tumor growth-related signaling pathway were estimated by H&E and immunohistochemical staining. SW480 tumor cells with higher IL-6R expression levels showed better responsiveness in tocilizumab therapy than in the treated HT-29 group. Likewise, therapeutic effects of tocilizumab on the proliferative ability with mitotic index and Ki-67 expressions, invasiveness with MMP-9 proteinase expressions, and ERK 1/2 and STAT3 signaling transduction in the SW480 treatment group were superior to the HT-29 treatment group. In light of our results, IL-6R is the key indicator for the efficacy of tocilizumab treatment in CRC xenografts. From the perspective of precision medicine, tumor response to anti-IL-6R antibody therapy could be predicted on the basis of IL-6R expression levels. In this manner, tocilizumab may serve as a targeted and promising anti-CRC therapy.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2024 Tipo de documento: Article